Stay updated with breaking news from Biosimilars Canada. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ontario is the eighth Canadian jurisdiction to switch patients with Crohn's disease and other conditions from life-changing biologic drugs to more cost-effective 'biosimilars.' Both options are considered effective, and the swap saves millions. But should patients be forced to make the change?
The province of Newfoundland and Labrador and the territory of Yukon both announced biosimilar switching policies, bringing Canada to a total of 10 out of 13 jurisdictions have a policy in place.
New Brunswick Becomes Third Province in Canada to Implement Biosimilar Switching Policy News provided by Share this article Share this article TORONTO, April 21, 2021 /CNW/ - Biosimilars Canada, a national association representing Canada's biosimilar medicines industry, today congratulated the Government of New Brunswick for implementing a biosimilar "switching" or transitioning policy to expand the use of biosimilar medicines under the province's public drug plans. New Brunswick's new biosimilar policy is expected to save the province more than $10 million annually when fully implemented, w...